- VTX-27
-
- $85.00 / 1mg
-
2026-02-03
- CAS:1321924-70-2
- Min. Order:
- Purity: 99.84%
- Supply Ability: 10g
- VTX-27
-
- $85.00 / 1mg
-
2026-02-03
- CAS:1321924-70-2
- Min. Order:
- Purity: 99.84%
- Supply Ability: 10g
|
| Product Name: | VTX-27 | | Synonyms: | VTX-27;VTX-27 ≥95%;2-Piperazinemethanol, 4-[3-chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)-2-pyridinyl]-α-methyl-α-(1-methylethyl)-, (αR,2S)-;(R)-2-((S)-4-(3-Chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)-3-methylbutan-2-ol;Inhibitor,VTX27,VTX 27,PKC,Protein kinase C,inhibit,VTX-27;(R)-2-((S)-4-(3-Chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)-3-methylbutan-2-ol , VTX-27;VTX-27, 10 mM in DMSO | | CAS: | 1321924-70-2 | | MF: | C20H24ClFN6O | | MW: | 418.9 | | EINECS: | | | Product Categories: | | | Mol File: | 1321924-70-2.mol |  |
| | VTX-27 Chemical Properties |
| Boiling point | 625.8±55.0 °C(Predicted) | | density | 1.342±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: soluble | | form | A solid | | pka | 7.24±0.40(Predicted) | | color | White to off-white |
| | VTX-27 Usage And Synthesis |
| Uses | VTX-27 is a selective protein kinase C θ (PKC θ) inhibitor, with Kis of 0.08 nM and 16 nM for PKC θ and PKC δ. | | in vivo | VTX-27 shows the best PK profile with a low clearance (7 mL min-1 kg-1), long half-life (4.7 h), and good oral bioavailability (65%). A single dose of VTX-27 is administered orally at 6.25, 12.5, 25, and 50 mg/kg (e.g., at 25 mg/kg Cmax concentration 700 ng/mL) and demonstrates potent dose dependent inhibition of IL-2 production[1]. | | IC 50 | PKCθ: 0.08 nM (Ki); PKCδ: 16 nM (Ki); PKCα: 356 nM (Ki) | | References | [1] Jimenez JM, et al. Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases. J Med Chem. 2013 Mar 14;56(5):1799-810. DOI:10.1021/jm301465a |
| | VTX-27 Preparation Products And Raw materials |
|